Medical cannabis investment company Seed Innovations updated the market on its portfolio company Eurox, a Germany-based, European-focussed vertically integrated medical cannabis company, on Tuesday. The AIM-traded firm said that when it made its investment in July, Eurox was expecting to launch its own brand within “months”. Seed confirmed on Tuesday that Eurox had successfully launched its own “unique” brand of ‘made in Germany’ full-spectrum medical cannabis extracts, representing a milestone for the company, with products now available for German pharmacies to order. The seed has an 8.85% shareholding in Eurox. It said Eurox’s objective with the new launch was to guarantee medical cannabis patients in Europe the “highest European pharmaceutical quality standards”, and to reduce the dependency of patients on long-distance international shipments and “burdensome” import-export permits. Eurox’s first launch of extracts had balanced tetrahydrocannabinol (THC) and cannabidiol (CBD) content. Seed said Eurox was continuing to work on the development and manufacturing of new products, with high-THC full-spectrum extracts, as well as pure dronabinol, expected to be launched in the coming months.

Sean Hocking, Cannabis Law Report, 08/18/2021 22:32:00

Open article: